Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers
Authors
Keywords
Anticancer, Inhibitors, Apoptosis, Quinolin, Molecular docking
Journal
BIOORGANIC CHEMISTRY
Volume 114, Issue -, Pages 105200
Publisher
Elsevier BV
Online
2021-07-30
DOI
10.1016/j.bioorg.2021.105200
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Design and synthesis of a novel class EGFR/HER2 dual inhibitors containing tricyclic oxazine fused quinazolines scaffold
- (2020) Min Sun et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models
- (2020) Debasis Das et al. BIOORGANIC CHEMISTRY
- Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers
- (2019) Souad A. Elmetwally et al. BIOORGANIC CHEMISTRY
- Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors
- (2019) Belgin Sever et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2
- (2019) Hamad M. Alkahtani et al. BIOORGANIC CHEMISTRY
- Dual EGFR/HER2 inhibitors and apoptosis inducers: New benzo[ g ]quinazoline derivatives bearing benzenesulfonamide as anticancer and radiosensitizers
- (2018) Mostafa M. Ghorab et al. BIOORGANIC CHEMISTRY
- Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities – Part 1
- (2018) Debasis Das et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors
- (2017) Mansour S. Alsaid et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of N -(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC
- (2017) Yongfei Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
- (2017) Xin Li et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors
- (2017) Mostafa M. Ghorab et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
- (2016) Jennifer L. Hsu et al. CANCER AND METASTASIS REVIEWS
- Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold
- (2016) Siyuan Yin et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
- (2015) Elias E. Stratikopoulos et al. CANCER CELL
- Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
- (2015) S. Napolitano et al. CLINICAL CANCER RESEARCH
- Design and synthesis of Lapatinib derivatives containing a branched side chain as HER1/HER2 targeting antitumor drug candidates
- (2014) Aifeng Lyu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- c-Met Targeting Enhances the Effect of Irradiation and Chemical Agents against Malignant Colon Cells Harboring a KRAS Mutation
- (2014) Yingbo Li et al. PLoS One
- Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors
- (2013) Maria Letícia de Castro Barbosa et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
- (2011) S. Iqbal et al. ANNALS OF ONCOLOGY
- Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models
- (2011) M. P. Morelli et al. CLINICAL CANCER RESEARCH
- A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer
- (2010) Srikala S. Sridhar et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
- (2010) H. J. Ross et al. CLINICAL CANCER RESEARCH
- A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
- (2009) K.-K. Wong et al. CLINICAL CANCER RESEARCH
- The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38
- (2009) Melissa J. LaBonte et al. INTERNATIONAL JOURNAL OF CANCER
- EGFR and colon cancer: a clinical view
- (2008) Javier de Castro-Carpeño et al. Clinical & Translational Oncology
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started